Stablepharma Doses First Patient in Pivotal Phase 2b Trial After Positive Clinical Results
The pivotal 160-patient study represents the final clinical step towards commercialisation of SPVX02, Stablepharma's fridge-free, freeze-resistant Td vaccine. LONDON, ENG, UNITED KINGDOM, October 7, 2026 /EINPresswire.com/ -- Following …